O'Malley DM - Search Results

1

Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma.

Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Banerjee S, García-Donas J, Swisher EM, Cella D, Meunier J, Goble S, Cameron T, Maloney L, Mörk AC, Bedel J, Ledermann JA, Coleman RL. Oza AM, et al. J Clin Oncol. 2020 Oct 20;38(30):3494-3505. doi: 10.1200/JCO.19.03107. Epub 2020 Aug 24. J Clin Oncol. 2020. PMID: 32840418 Free PMC article.

2

A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): a Gynecologic Oncology Group Study.

Sabbatini P, Sill MW, O'Malley D, Adler L, Secord AA; Gynecologic Oncology Group Study. Sabbatini P, et al. Gynecol Oncol. 2008 Dec;111(3):455-60. doi: 10.1016/j.ygyno.2008.07.049. Epub 2008 Sep 30. Gynecol Oncol. 2008. PMID: 18829087 Clinical Trial.

3

Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer.

Richardson DL, Backes FJ, Seamon LG, Zanagnolo V, O'Malley DM, Cohn DE, Fowler JM, Copeland LJ. Richardson DL, et al. Gynecol Oncol. 2008 Dec;111(3):461-6. doi: 10.1016/j.ygyno.2008.08.011. Epub 2008 Sep 30. Gynecol Oncol. 2008. PMID: 18829088

4

Epithelial ovarian cancer.

Morgan RJ Jr, Alvarez RD, Armstrong DK, Boston B, Burger RA, Chen LM, Copeland L, Crispens MA, Gershenson D, Gray HJ, Grigsby PW, Hakam A, Havrilesky LJ, Johnston C, Lele S, Matulonis UA, O'Malley DM, Penson RT, Remmenga SW, Sabbatini P, Schilder RJ, Schink JC, Teng N, Werner TL; National Comprehensive Cancer Network. Morgan RJ Jr, et al. J Natl Compr Canc Netw. 2011 Jan;9(1):82-113. doi: 10.6004/jnccn.2011.0008. J Natl Compr Canc Netw. 2011. PMID: 21233246 No abstract available.

5

Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer.

O'Malley DM, Richardson DL, Rheaume PS, Salani R, Eisenhauer EL, McCann GA, Fowler JM, Copeland LJ, Cohn DE, Backes FJ. O'Malley DM, et al. Gynecol Oncol. 2011 May 1;121(2):269-72. doi: 10.1016/j.ygyno.2011.01.009. Epub 2011 Feb 18. Gynecol Oncol. 2011. PMID: 21315428

6

At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis.

Cohn DE, Kim KH, Resnick KE, O'Malley DM, Straughn JM Jr. Cohn DE, et al. J Clin Oncol. 2011 Apr 1;29(10):1247-51. doi: 10.1200/JCO.2010.32.1075. Epub 2011 Mar 7. J Clin Oncol. 2011. PMID: 21383297

7

Effect of chemotherapy delays and dose reductions on progression free and overall survival in the treatment of epithelial ovarian cancer.

Nagel CI, Backes FJ, Hade EM, Cohn DE, Eisenhauer EL, O'Malley DM, Fowler JM, Copeland LJ, Salani R. Nagel CI, et al. Gynecol Oncol. 2012 Feb;124(2):221-4. doi: 10.1016/j.ygyno.2011.10.003. Epub 2011 Nov 4. Gynecol Oncol. 2012. PMID: 22055764 Free PMC article.

8

Short- and long-term morbidity and outcomes after robotic surgery for comprehensive endometrial cancer staging.

Backes FJ, Brudie LA, Farrell MR, Ahmad S, Finkler NJ, Bigsby GE, O'Malley D, Cohn DE, Holloway RW, Fowler JM. Backes FJ, et al. Gynecol Oncol. 2012 Jun;125(3):546-51. doi: 10.1016/j.ygyno.2012.02.023. Epub 2012 Mar 3. Gynecol Oncol. 2012. PMID: 22387522

9

A multicenter evaluation of adjuvant therapy in women with optimally resected stage IIIC endometrial cancer.

Secord AA, Geller MA, Broadwater G, Holloway R, Shuler K, Dao NY, Gehrig PA, O'Malley DM, Finkler N, Havrilesky LJ. Secord AA, et al. Gynecol Oncol. 2013 Jan;128(1):65-70. doi: 10.1016/j.ygyno.2012.10.010. Epub 2012 Oct 17. Gynecol Oncol. 2013. PMID: 23085460

10

Ovarian cancer, version 3.2012.

Morgan RJ Jr, Alvarez RD, Armstrong DK, Burger RA, Castells M, Chen LM, Copeland L, Crispens MA, Gershenson D, Gray H, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulonis UA, O'Malley DM, Penson RT, Remmenga SW, Sabbatini P, Santoso JT, Schilder RJ, Schink J, Teng N, Werner TL, Hughes M, Dwyer MA; National Comprehensive Cancer Network. Morgan RJ Jr, et al. J Natl Compr Canc Netw. 2012 Nov 1;10(11):1339-49. doi: 10.6004/jnccn.2012.0140. J Natl Compr Canc Netw. 2012. PMID: 23138163

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

299 results

Search Page

Filters